Subtopic Deep Dive

Manufacturing Changes Impact on Biosimilar Immunogenicity
Research Guide

What is Manufacturing Changes Impact on Biosimilar Immunogenicity?

Manufacturing Changes Impact on Biosimilar Immunogenicity examines how process variations, glycosylation profiles, host cell impurities, and packaging factors alter immune response risks in biosimilars such as rituximab, filgrastim, and epoetin alfa.

This subtopic centers on comparative physicochemical characterization to assess immunogenicity risks from manufacturing differences between biosimilars and originators. Key factors include posttranslational modifications and aggregation induced by elements like tungsten in pre-filled syringes. Over 10 papers from the provided list address these issues, with foundational works exceeding 200 citations each.

Curated Papers

Key Challenges

Why It Matters

Ensuring manufacturing consistency minimizes unwanted immune responses in biosimilars, critical for safe clinical use in treatments like anemia (Kalantar‐Zadeh, 2017, 1148 citations) and oncology. Tungsten-induced denaturation of epoetin alfa in packaging caused immunogenicity outbreaks, highlighting process control needs (Seidl et al., 2011, 196 citations). Posttranslational modifications from manufacturing changes directly associate with biotherapeutic immunogenicity, guiding regulatory approval (Kuriakose et al., 2016, 207 citations). Physicochemical comparability, as shown for rituximab biosimilar GP2013, supports functional similarity and reduces risks (Visser et al., 2013, 178 citations).

Key Research Challenges

Detecting Subtle Glycosylation Changes

Glycosylation profiles vary due to host cell lines and process parameters, impacting immunogenicity. Sensitive bioanalytical methods are required for detection. Kuriakose et al. (2016) link these modifications to immune responses in biotherapeutics.

Quantifying Host Cell Impurities

Host cell proteins and DNA impurities from manufacturing persist and trigger immunogenicity. Standardized assays struggle with low-level detection in complex mixtures. Kessler et al. (2006) emphasize impurities as primary biosimilar safety concerns.

Assessing Packaging-Induced Aggregation

Tungsten from pre-filled syringes denatures proteins like epoetin alfa, causing aggregation and antibodies. Replicating clinical immunogenicity in models is challenging. Seidl et al. (2011) identify tungsten as a root cause in epoetin immunogenicity.

Essential Papers

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Kamyar Kalantar‐Zadeh · 2017 · American Journal of Nephrology · 1.1K citations

<b><i>Background:</i></b> Exogenous replacement of erythropoietin (EPO) by recombinant human EPO has been considered a standard of care for the treatment of anemia in patien...

Biopharmaceutical benchmarks 2022

Gary Walsh, Eithne Walsh · 2022 · Nature Biotechnology · 441 citations

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

William R. Strohl · 2015 · BioDrugs · 431 citations

The purpose of making a "biobetter" biologic is to improve on the salient characteristics of a known biologic for which there is, minimally, clinical proof of concept or, maximally, marketed produc...

Biosimilars: what clinicians should know

Martina Weise, Marie-Christine Bielsky, Karen De Smet et al. · 2012 · Blood · 343 citations

Abstract Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the United States. Despite an established legal pathway for biosimilar...

Progress in biopharmaceutical development

Małgorzata Kęsik-Brodacka · 2017 · Biotechnology and Applied Biochemistry · 335 citations

Abstract Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In r...

Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges

Yulia Vugmeyster · 2012 · World Journal of Biological Chemistry · 236 citations

Significant progress has been made in understanding pharmacokinetics (PK), pharmacodynamics (PD), as well as toxicity profiles of therapeutic proteins in animals and humans, which have been in comm...

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

Silvio Danese, Gionata Fiorino, Tim Raine et al. · 2016 · Journal of Crohn s and Colitis · 232 citations

sponsorship: SD has served as a speaker, consultant, and advisory board member for Schering-Plough, Abbott Laboratories, Merck, UCB-pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmo...

Reading Guide

Foundational Papers

Start with Kessler et al. (2006, 204 citations) for biopharmaceutical immunogenicity basics, then Seidl et al. (2011, 196 citations) for tungsten packaging cause in epoetin, and Weise et al. (2012, 343 citations) for clinician biosimilar overview.

Recent Advances

Study Kuriakose et al. (2016, 207 citations) on posttranslational modifications, Visser et al. (2013, 178 citations) on rituximab physicochemical comparability, and Cohen et al. (2018, 206 citations) on switching outcomes.

Core Methods

Physicochemical characterization (primary structure, glycosylation, size variants); functional assays (binding, potency); immunogenicity assays (ADA detection, neutralization).

How PapersFlow Helps You Research Manufacturing Changes Impact on Biosimilar Immunogenicity

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map high-citation works like Seidl et al. (2011, 196 citations) on tungsten-induced epoetin immunogenicity, then findSimilarPapers reveals related rituximab studies (Visser et al., 2013). exaSearch uncovers process-specific queries on glycosylation impacts from Kuriakose et al. (2016).

Analyze & Verify

Analysis Agent applies readPaperContent to extract physicochemical data from Visser et al. (2013) rituximab comparability, then verifyResponse with CoVe checks claims against abstracts. runPythonAnalysis processes glycosylation profile stats with pandas for statistical verification; GRADE grading scores evidence strength for manufacturing risk claims.

Synthesize & Write

Synthesis Agent detects gaps in immunogenicity data across filgrastim papers via gap detection and flags contradictions in aggregation risks. Writing Agent uses latexEditText for methods sections, latexSyncCitations for Seidl et al. (2011), and latexCompile for full reports; exportMermaid visualizes manufacturing change → immunogenicity pathways.

Use Cases

"Analyze glycosylation data from rituximab biosimilar papers for immunogenicity risk stats"

Research Agent → searchPapers('rituximab biosimilar glycosylation') → Analysis Agent → readPaperContent(Visser 2013) → runPythonAnalysis(pandas quantile analysis on glycan peaks) → statistical output with p-values and risk correlations.

"Draft LaTeX report on tungsten epoetin immunogenicity with citations"

Research Agent → citationGraph(Seidl 2011) → Synthesis Agent → gap detection → Writing Agent → latexEditText(manufacturing section) → latexSyncCitations(Kessler 2006, Kuriakose 2016) → latexCompile → PDF report.

"Find code for modeling biosimilar aggregation from manufacturing changes"

Research Agent → paperExtractUrls(aggregation papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for protein folding simulations applied to epoetin data.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ biosimilar papers, chaining searchPapers → citationGraph → GRADE grading for manufacturing immunogenicity evidence. DeepScan applies 7-step analysis with CoVe checkpoints to verify tungsten claims in Seidl et al. (2011). Theorizer generates hypotheses on glycosylation-process links from Kuriakose et al. (2016) data.

Try Doxa for Manufacturing Changes Impact on Biosimilar Immunogenicity Research

Frequently Asked Questions

What defines manufacturing changes impact on biosimilar immunogenicity?

Process variations like glycosylation shifts, impurities, and packaging factors alter immune responses in biosimilars versus originators, assessed via physicochemical characterization.

What methods detect these immunogenicity risks?

Comparative assays for structure, posttranslational modifications, and aggregation; examples include glycan profiling and host cell protein ELISA, as in Visser et al. (2013) for rituximab.

What are key papers on this subtopic?

Seidl et al. (2011, 196 citations) on tungsten-induced epoetin aggregation; Kuriakose et al. (2016, 207 citations) on posttranslational modifications; Kessler et al. (2006, 204 citations) on biopharmaceutical immunogenicity.

What open problems remain?

Predicting clinical immunogenicity from in vitro manufacturing changes; standardizing low-level impurity detection; modeling aggregation risks across biosimilars like filgrastim.